X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (392) 392
index medicus (317) 317
oncology (273) 273
female (266) 266
epothilones - administration & dosage (172) 172
epothilones - therapeutic use (152) 152
chemotherapy (150) 150
breast neoplasms - drug therapy (149) 149
ixabepilone (149) 149
cancer (147) 147
antineoplastic agents - therapeutic use (141) 141
paclitaxel (132) 132
animals (121) 121
middle aged (117) 117
epothilones (115) 115
epothilones - adverse effects (114) 114
pharmacology & pharmacy (111) 111
breast cancer (110) 110
male (109) 109
epothilone-b analog (105) 105
aged (104) 104
adult (102) 102
epothilones - pharmacology (98) 98
antineoplastic agents - pharmacology (88) 88
microtubule-stabilizing agents (87) 87
antineoplastic combined chemotherapy protocols - therapeutic use (85) 85
treatment outcome (83) 83
bms-247550 (82) 82
antineoplastic agents - administration & dosage (81) 81
antineoplastic agents - adverse effects (79) 79
breast neoplasms - pathology (79) 79
care and treatment (78) 78
epothilone (75) 75
neoplasms - drug therapy (74) 74
drug resistance, neoplasm (73) 73
research (73) 73
drug therapy (69) 69
capecitabine (68) 68
antineoplastic agents (67) 67
tubulin modulators - therapeutic use (67) 67
hematology, oncology and palliative medicine (65) 65
anthracycline (63) 63
phase-ii (61) 61
taxane (61) 61
neoplasm metastasis (60) 60
mice (59) 59
clinical trials as topic (58) 58
epothilones - pharmacokinetics (58) 58
medicine & public health (58) 58
antimitotic agents (57) 57
metastatic breast-cancer (57) 57
ii clinical-trial (54) 54
metastasis (51) 51
microtubules - drug effects (51) 51
microtubules (50) 50
clinical trials (49) 49
dose-response relationship, drug (49) 49
taxoids - therapeutic use (49) 49
clinical-trial (48) 48
docetaxel (46) 46
dosage and administration (45) 45
drug administration schedule (45) 45
ixabepilone bms-247550 (45) 45
metastatic breast cancer (45) 45
tubulin (45) 45
deoxycytidine - analogs & derivatives (44) 44
phase-ii trial (44) 44
solid tumors (43) 43
taxanes (43) 43
health aspects (42) 42
aged, 80 and over (41) 41
plus capecitabine (41) 41
tubulin modulators - pharmacology (41) 41
epothilone b (40) 40
pharmacology/toxicology (39) 39
analysis (38) 38
anthracyclines (38) 38
cell line, tumor (38) 38
patupilone (38) 38
antineoplastic agents - pharmacokinetics (37) 37
tubulin modulators - administration & dosage (37) 37
epothilone d (36) 36
tumors (36) 36
article (35) 35
resistant (35) 35
cell lung-cancer (34) 34
epothilones - chemistry (34) 34
fluorouracil - analogs & derivatives (34) 34
neurosciences (34) 34
taxol (34) 34
antineoplastic combined chemotherapy protocols - adverse effects (33) 33
disease-free survival (33) 33
drug resistance (33) 33
obstetrics and gynecology (33) 33
peripheral nervous system diseases - chemically induced (32) 32
microtubules - metabolism (31) 31
tubulin modulators - adverse effects (31) 31
deoxycytidine - administration & dosage (30) 30
trial (30) 30
epothilone-b (29) 29
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer Letters, ISSN 0304-3835, 2012, Volume 320, Issue 1, pp. 104 - 110
Abstract Molecularly targeted therapies have emerged as the leading theme in cancer therapeutics. Multi-cytotoxic drug regimens have been highly successful,... 
Hematology, Oncology and Palliative Medicine | Combination index | Dasatinib | Molecular targeted therapy | Rapamycin | ACTIVATION | SRC | BCR-ABL | TUMOR | MECHANISMS | SIMULATION | CHEMOTHERAPY | ONCOLOGY | RESISTANCE | SYSTEMS | KINASES | Niacinamide - analogs & derivatives | Paclitaxel - pharmacology | Nitriles - pharmacology | Humans | Epothilones - pharmacology | Thiazoles - administration & dosage | Chromones - administration & dosage | Phenylurea Compounds | Benzenesulfonates - administration & dosage | Tamoxifen - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Benzenesulfonates - pharmacology | Female | Chromones - pharmacology | Paclitaxel - administration & dosage | Butadienes - pharmacology | Pyridines - administration & dosage | Pyrimidines - administration & dosage | Morpholines - administration & dosage | Enzyme Inhibitors - pharmacology | Morpholines - pharmacology | Pyrimidines - pharmacology | Breast Neoplasms - drug therapy | Sirolimus - pharmacology | Drug Synergism | Sirolimus - administration & dosage | Signal Transduction - drug effects | Butadienes - administration & dosage | Epothilones - administration & dosage | Tamoxifen - pharmacology | Cell Line, Tumor | Pyridines - pharmacology | Thiazoles - pharmacology | Care and treatment | Oncology, Experimental | Genes | Breast cancer | Research | Tamoxifen | Cancer | Cell culture | Values | Cell division | Cytotoxicity | Regression analysis | Kinases | Cancer therapies | Cell growth | Cell cycle | Software | Mutation | Drug dosages | Methods | Tumors | Apoptosis | Index Medicus
Journal Article
Journal Article
Acta Pharmaceutica Sinica B, ISSN 2211-3835, 09/2016, Volume 6, Issue 5, pp. 460 - 467
To assess targeting of an epothilone folate conjugate (BMS-753493) to the folate receptor (FR)-overexpressed tumor in mice bearing both FR+ and FR- tumors, a... 
Folate receptor-expressing tumor | Tumor selective targeting | Folate receptor | Tissue distribution | Epothilone folate conjugate | Tumor uptake | ACID | BINDING-PROTEIN | OVARIAN-CANCER | CELL-LINES | TRIAL | Folate receptor expressing tumor | IXABEPILONE | PHARMACOLOGY & PHARMACY | AGENTS | Folate receptor–expressing tumor | Original
Journal Article
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 12/2017, Volume 268, pp. 176 - 183
Journal Article
Experimental Neurology, ISSN 0014-4886, 08/2018, Volume 306, pp. 243 - 249
Central nervous system (CNS) injuries cause permanent impairments of sensorimotor functions as mature neurons fail to regenerate their severed axons. The poor... 
Axon growth | Epothilone D | Axon regeneration | Scarring | Microtubule stabilization | ADULT CNS | SCAR | ABILITY | CORTICOSPINAL TRACT | PROMOTES AXON REGENERATION | NEUROSCIENCES | MODULATION | Nervous system diseases | Therapeutics | Spinal cord injuries | Liquid chromatography | Mass spectrometry | Homeopathy | Materia medica and therapeutics
Journal Article
International Journal of Pharmaceutics, ISSN 0378-5173, 02/2017, Volume 518, Issue 1-2, pp. 307 - 311
Epothilones are microtubule inhibitors that are promising alternatives to paclitaxel due to enhanced anticancer efficacy. While epothilones are slightly more... 
Epothilone B | Drug combination | Polymeric micelle | Multiple drug solubilization | Non-small cell lung cancer | RAPAMYCIN | VITRO | AKT ACTIVATION | INHIBITS GROWTH | ANTITUMOR-ACTIVITY | PACLITAXEL | BREAST-CANCER CELLS | LUNG-CANCER | PATUPILONE | IN-VIVO | PHARMACOLOGY & PHARMACY | Benzoquinones - administration & dosage | Epothilones - chemistry | Humans | Polyethylene Glycols - chemistry | Antineoplastic Agents - therapeutic use | Benzoquinones - chemistry | Antineoplastic Agents - administration & dosage | Epothilones - therapeutic use | Polyethylene Glycols - therapeutic use | TOR Serine-Threonine Kinases - antagonists & inhibitors | Lactams, Macrocyclic - chemistry | Micelles | Female | Lactams, Macrocyclic - administration & dosage | Lactams, Macrocyclic - therapeutic use | A549 Cells | Cell Survival - drug effects | Sirolimus - therapeutic use | Antineoplastic Agents - chemistry | Polyethylene Glycols - administration & dosage | Neoplasms - drug therapy | Sirolimus - administration & dosage | Animals | Tumor Burden - drug effects | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Mice, Nude | Epothilones - administration & dosage | Drug Liberation | Sirolimus - chemistry | Neoplasms - pathology | Benzoquinones - therapeutic use | Drug Combinations | Antimitotic agents | Antineoplastic agents | Ethylene glycol | Pharmacy | Drugstores | Heat shock proteins | Drug therapy, Combination | Drug resistance | Drug therapy | Lung cancer, Non-small cell | Organic acids | polymeric micelle | non-small cell lung cancer | drug combination | multiple drug solubilization
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2014, Volume 9, Issue 9, p. e108405
Triple negative breast cancer (TNBC) is associated with high pathological complete remission (pCR) rate in neoadjuvant treatment (NAT). TNBC patients who... 
WOMEN | PREOPERATIVE CHEMOTHERAPY | THERAPY | TRASTUZUMAB | EFFICACY | PRIMARY SYSTEMIC TREATMENT | MULTIDISCIPLINARY SCIENCES | INTERNATIONAL EXPERT PANEL | PHASE-III | OPEN-LABEL | PACLITAXEL | Capecitabine - administration & dosage | Multicenter Studies as Topic - statistics & numerical data | Carcinoma, Ductal, Breast - surgery | Randomized Controlled Trials as Topic - statistics & numerical data | Bevacizumab - administration & dosage | Deoxycytidine - administration & dosage | Humans | Carboplatin - administration & dosage | Treatment Outcome | Triple Negative Breast Neoplasms - drug therapy | Remission Induction | Taxoids - administration & dosage | Carcinoma, Ductal, Breast - drug therapy | Anthracyclines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Triple Negative Breast Neoplasms - surgery | Epothilones - administration & dosage | Triple Negative Breast Neoplasms - pathology | Mastectomy | Carcinoma, Ductal, Breast - pathology | Female | Neoadjuvant Therapy | Deoxycytidine - analogs & derivatives | Care and treatment | Breast cancer | Angiogenesis inhibitors | Analysis | Adjuvant treatment | Cancer | Estrogens | Medical services | Clinical trials | Estrogen receptors | Mammography | Metastasis | FDA approval | Gene expression | Cancer therapies | Patients | ErbB-2 protein | Bevacizumab | Medicine | Confidence intervals | Studies | Chemotherapy | Hospitals | Medical prognosis | Carboplatin | Breast | Remission
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2007, Volume 25, Issue 33, pp. 5210 - 5217
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 3, pp. 371 - 383
Journal Article